沙利度胺治疗晚期非小细胞肺癌的临床疗效观察

Observe the clinical effect of thalidomide in the treatment of small cell lung cancer

目的：探讨沙利度胺联合化疗对非小细胞肺癌的临床疗效。方法：将我院治疗的85倒中晚期非小细胞肺癌患者随机分为观察组45例和对照组40例．对照组采用常规化疗方法，观察组在对照组基础上加用沙利度胺，对比两组近期疗效、不良反应发生率、疼痛缓解率以及1、2年生存期。结果：治疗一个疗程后，观察组近期疗效和疼痛缓解率显著优于对照组（P〈0.05）；此外，观察组在白细胞、粒细胞、血小板减少以及恶心呕吐等不良反应的发生率显著低于对照组（P〈0.05）。对患者进行1～2年随访，治疗组1年的生存率为822％，2年生存率为57．8％，对照组分别为57．5％和35.0％，两组相比，有统计学差异（P〈0.05）。结论：沙利度胺治疗NSCLC疗效确切，不良反应发生率低，患者远期生存率有所提高，值得临床推广。

Objective： To explore the clinical effect of thalidomide combined with chemotherapy for non-small cell lung cancer.Methods： Select 140 cases of advanced non-small cell lung cancer in our hospital,were randomly divided into the observation group 45 cases and control group with 40 cases.The control group received conventional chemotherapy method,the observation group on the basis of control group with thalidomide.Compared two groups of curative effect in the near future, the incidence of adverse reactions, pain relief rate and a 1, 2 year survival.Results： After a cottrse of treatment, observation of therapeutic effect and the pain relief rate was significantly better than the control group （P〈0.05）.The observation group in the leukocyte, granulooyte, thromboeytopenia, nausea and vomiting and other adverse reaction rate was significantly lower than that of the control group （P〈0＋05）.l to 2 of patients with follow-up, survival rate of treatment group 1 years was 82.2%, 2 year survival rate was 57.8%, the control group were 57.5% and 35%, compared to the two groups, there were significant differences （P〈0.05）.Conelusion： Thalidomide in the treatment of NSCLC curative effect, low incidence of adverse reactions, patients long-term survival rate increases, and worth the clinical promotion.